Iambic Therapeutics

Iambic Therapeutics, formerly known as Entos, is a biopharmaceutical company leveraging AI-driven technologies to revolutionize drug discovery and development. Their advanced physics-based AI platform optimizes molecular designs to address complex biological challenges and unmet medical needs. With a focus on transforming both known and undruggable targets, Iambic Therapeutics aims to deliver first-in-class and best-in-class clinical candidates efficiently and effectively. The company's proprietary high-throughput experimental capabilities enable rapid conversion of innovative molecular designs into actionable biological data.

Product Breakdown
Iambic Therapeutics offers a comprehensive AI-driven platform designed to enhance the drug discovery process. This platform employs sophisticated physics-based algorithms to explore chemical spaces deeply, identifying novel mechanisms of action and producing high-quality lead compounds. 

Key products include:

HER2 Inhibitors: These compounds exhibit 1000x selectivity and brain penetrance, aiming to unlock therapeutic potential for metastatic diseases.
CDK2/4 Inhibitors: First-in-class profiles addressing cyclin D and E driven cancers while minimizing off-target toxicities.
Novel Target Programs: Focusing on cryptic pockets, allostery, and protein-protein interactions across multiple therapeutic areas.